HomeComparePROG vs MCD

PROG vs MCD: Dividend Comparison 2026

PROG yields 226.12% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROG wins by $247.24M in total portfolio value
10 years
PROG
PROG
● Live price
226.12%
Share price
$0.88
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$247.32M
Annual income
$132,258,559.01
Full PROG calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — PROG vs MCD

📍 PROG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROGMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROG + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROG pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROG
Annual income on $10K today (after 15% tax)
$19,219.90/yr
After 10yr DRIP, annual income (after tax)
$112,419,775.16/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, PROG beats the other by $112,397,481.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROG + MCD for your $10,000?

PROG: 50%MCD: 50%
100% MCD50/50100% PROG
Portfolio after 10yr
$123.70M
Annual income
$66,142,393.36/yr
Blended yield
53.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

PROG
Analyst Ratings
2
Buy
2
Hold
1
Sell
Consensus: Buy
Price Target
$4.00
+352.2% upside vs current
Range: $4.00 — $4.00
Altman Z
-19.8
Piotroski
4/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROG buys
0
MCD buys
0
No recent congressional trades found for PROG or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROGMCD
Forward yield226.12%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$247.32M$78.5K
Annual income after 10y$132,258,559.01$26,227.70
Total dividends collected$234.58M$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$4.00$351.76

Year-by-year: PROG vs MCD ($10,000, DRIP)

YearPROG PortfolioPROG Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$33,312$22,611.64$10,815$334.85+$22.5KPROG
2$106,039$70,395.43$11,826$491.71+$94.2KPROG
3$322,887$209,425.60$13,123$730.06+$309.8KPROG
4$941,469$595,979.98$14,853$1,100.07+$926.6KPROG
5$2,631,436$1,624,064.27$17,257$1,690.61+$2.61MPROG
6$7,057,984$4,242,346.63$20,752$2,667.01+$7.04MPROG
7$18,186,373$10,634,330.10$26,103$4,354.83+$18.16MPROG
8$45,068,370$25,608,951.52$34,794$7,437.78+$45.03MPROG
9$107,533,957$59,310,801.02$49,926$13,461.60+$107.48MPROG
10$247,319,893$132,258,559.01$78,550$26,227.70+$247.24MPROG

PROG vs MCD: Complete Analysis 2026

PROGStock

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Full PROG Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this PROG vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROG vs SCHDPROG vs JEPIPROG vs OPROG vs KOPROG vs MAINPROG vs YUMPROG vs QSRPROG vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.